Track topics on Twitter Track topics that are important to you
KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory conditions.
KIACTA™ is partenered with global private equity firm Auven Therapeutics (previously Celtic Therapeutics). Patients are currently being enrolled in a Phase III Confirmatory Study for KIACTA™. This pivotal study will be used to confirm the positive safety and efficacy results shown in the Phase II/III study previously conducted BELLUS Health.
SummaryBELLUS Health Inc BELLUS Health is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company's pipeline products include BLU5937 for chronic coug...
Auven Therapeutics is a private equity company focused on the healthcare industry. The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms. ...
The main objectives of the current study are to establish the safety and clinical proof-of-concept of NC-503 in inadequately controlled patients with Type 2 diabetes and features of metabo...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...